Cargando…

Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging

OBJECTIVES: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Roczniak, Jan, Bączalska, Justyna, Kanclerz, Gabriela, Zielińska, Weronika, Ożga, Joanna, Cymerman, Błażej, Stępień, Agnieszka, Kostkiewicz, Magdalena, Holcman, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284185/
https://www.ncbi.nlm.nih.gov/pubmed/37337782
http://dx.doi.org/10.4274/mirt.galenos.2022.72593
_version_ 1785061352827518976
author Roczniak, Jan
Bączalska, Justyna
Kanclerz, Gabriela
Zielińska, Weronika
Ożga, Joanna
Cymerman, Błażej
Stępień, Agnieszka
Kostkiewicz, Magdalena
Holcman, Katarzyna
author_facet Roczniak, Jan
Bączalska, Justyna
Kanclerz, Gabriela
Zielińska, Weronika
Ożga, Joanna
Cymerman, Błażej
Stępień, Agnieszka
Kostkiewicz, Magdalena
Holcman, Katarzyna
author_sort Roczniak, Jan
collection PubMed
description OBJECTIVES: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI. METHODS: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson. The collected data included the patients’ characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements. RESULTS: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001). CONCLUSION: Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP.
format Online
Article
Text
id pubmed-10284185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-102841852023-06-22 Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging Roczniak, Jan Bączalska, Justyna Kanclerz, Gabriela Zielińska, Weronika Ożga, Joanna Cymerman, Błażej Stępień, Agnieszka Kostkiewicz, Magdalena Holcman, Katarzyna Mol Imaging Radionucl Ther Original Article OBJECTIVES: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI. METHODS: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson. The collected data included the patients’ characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements. RESULTS: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001). CONCLUSION: Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP. Galenos Publishing 2023-06 2023-06-20 /pmc/articles/PMC10284185/ /pubmed/37337782 http://dx.doi.org/10.4274/mirt.galenos.2022.72593 Text en ©Copyright 2023 by the Turkish Society of Nuclear Medicine / Molecular Imaging and Radionuclide Therapy published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Roczniak, Jan
Bączalska, Justyna
Kanclerz, Gabriela
Zielińska, Weronika
Ożga, Joanna
Cymerman, Błażej
Stępień, Agnieszka
Kostkiewicz, Magdalena
Holcman, Katarzyna
Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
title Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
title_full Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
title_fullStr Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
title_full_unstemmed Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
title_short Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging
title_sort comparison of regadenoson and dipyridamole safety profiles during stress myocardial perfusion imaging
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284185/
https://www.ncbi.nlm.nih.gov/pubmed/37337782
http://dx.doi.org/10.4274/mirt.galenos.2022.72593
work_keys_str_mv AT roczniakjan comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT baczalskajustyna comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT kanclerzgabriela comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT zielinskaweronika comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT ozgajoanna comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT cymermanbłazej comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT stepienagnieszka comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT kostkiewiczmagdalena comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging
AT holcmankatarzyna comparisonofregadenosonanddipyridamolesafetyprofilesduringstressmyocardialperfusionimaging